Literature DB >> 17004854

Prolactin-secreting tumors: what's new?

Mark E Molitch1.   

Abstract

Prolactinomas are a common cause of reproductive/sexual dysfunction. Once other causes of hyperprolactinemia have been excluded with a careful history and physical examination, routine chemistries, a pregnancy test and a thyroid-stimulating hormone, imaging with magnetic resonance imaging or computed tomography will delineate the size and extent of the tumor. Medical therapy with cabergoline or bromocriptine is the initial treatment of choice. When infertility is the primary indication for treatment, bromocriptine use has an extensive safety experience and is preferred by some clinicians. However, for other indications, cabergoline appears to be more efficacious and better tolerated. Transsphenoidal surgery remains an option, especially for patients with microadenomas, when medical therapy is ineffective or not tolerated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004854     DOI: 10.1586/14737140.6.9s.S29

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  7 in total

1.  Ectopic Pituitary Adenomas Presenting as Sphenoid or Clival Lesions: Case Series and Management Recommendations.

Authors:  Bobby A Tajudeen; Edward C Kuan; Nithin D Adappa; Joseph K Han; Rakesh K Chandra; James N Palmer; David W Kennedy; Marilene B Wang; Jeffrey D Suh
Journal:  J Neurol Surg B Skull Base       Date:  2016-09-09

2.  Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.

Authors:  Moon Sool Yang; Jae Won Hong; Seung Koo Lee; Eun Jig Lee; Sun Ho Kim
Journal:  J Neurooncol       Date:  2010-11-24       Impact factor: 4.130

3.  Epistaxis as first clinical presentation in a child with giant prolactinoma: Case report and review of literature.

Authors:  Pramod Kumar Chaurasia; Daljit Singh; Sujeet Meher; R K Saran; Hukum Singh
Journal:  J Pediatr Neurosci       Date:  2011-07

4.  Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.

Authors:  Yan-Nian Jiang; Yi-Hung Li; Meng-Wei Ke; Ting-Yu Tseng; Yueh-Bih Tang; Mu-Chiou Huang; Winston Teng-Kuei Cheng; Yu-Ten Ju
Journal:  Cancer Cell Int       Date:  2007-03-02       Impact factor: 5.722

5.  Bromocriptine therapy for the treatment of invasive prolactinoma: the single institute experience.

Authors:  Kyung Rae Cho; Kyung-Il Jo; Hyung Jin Shin
Journal:  Brain Tumor Res Treat       Date:  2013-10-31

6.  Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.

Authors:  Jinxiang Huang; Fenglin Zhang; Lei Jiang; Guohan Hu; Wei Sun; Chenran Zhang; Xuehua Ding
Journal:  Cancer Res Treat       Date:  2016-07-28       Impact factor: 4.679

7.  Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.

Authors:  Yi Zhao; Di Jin; Wei Lian; Bing Xing; Ming Feng; Xiaohai Liu; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.